Genscript Biotech Corporation (F:G51) — Market Cap & Net Worth
Market Cap & Net Worth: Genscript Biotech Corporation (G51)
Genscript Biotech Corporation (F:G51) has a market capitalization of $3.27 Billion (€2.80 Billion) as of June 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #4779 globally and #794 in its home market, demonstrating a -8.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genscript Biotech Corporation's stock price €1.28 by its total outstanding shares 2184705170 (2.18 Billion). Review debt load of Genscript Biotech Corporation to assess the company's total debt and financial obligations.
Genscript Biotech Corporation Market Cap History: 2016 to 2026
Genscript Biotech Corporation's market capitalization history from 2016 to 2026. Data shows growth from $1.10 Billion to $3.27 Billion (24.14% CAGR).
Genscript Biotech Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genscript Biotech Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.52x
Genscript Biotech Corporation's market cap is 3.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.10 Billion | $114.73 Million | $26.17 Million | 9.61x | 42.14x |
| 2017 | $5.44 Billion | $152.65 Million | $26.12 Million | 35.64x | 208.26x |
| 2018 | $2.91 Billion | $231.02 Million | $21.22 Million | 12.60x | 137.24x |
| 2019 | $5.16 Billion | $273.35 Million | -$96.91 Million | 18.87x | N/A |
| 2020 | $2.94 Billion | $390.33 Million | -$204.94 Million | 7.53x | N/A |
| 2021 | $9.09 Billion | $510.60 Million | -$347.87 Million | 17.81x | N/A |
| 2022 | $7.53 Billion | $625.70 Million | -$226.85 Million | 12.04x | N/A |
| 2023 | $5.68 Billion | $560.48 Million | -$95.48 Million | 10.14x | N/A |
| 2024 | $3.06 Billion | $594.49 Million | $2.96 Billion | 5.16x | 1.03x |
| 2025 | $3.38 Billion | $959.53 Million | -$532.83 Million | 3.52x | N/A |
Competitor Companies of G51 by Market Capitalization
Companies near Genscript Biotech Corporation in the global market cap rankings as of June 17, 2026.
Key companies related to Genscript Biotech Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Genscript Biotech Corporation Historical Marketcap From 2016 to 2026
Between 2016 and today, Genscript Biotech Corporation's market cap moved from $1.10 Billion to $ 3.27 Billion, with a yearly change of 24.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.27 Billion | -3.18% |
| 2025 | €3.38 Billion | +10.17% |
| 2024 | €3.06 Billion | -46.07% |
| 2023 | €5.68 Billion | -24.55% |
| 2022 | €7.53 Billion | -17.16% |
| 2021 | €9.09 Billion | +209.57% |
| 2020 | €2.94 Billion | -43.07% |
| 2019 | €5.16 Billion | +77.19% |
| 2018 | €2.91 Billion | -46.48% |
| 2017 | €5.44 Billion | +393.28% |
| 2016 | €1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Genscript Biotech Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.27 Billion USD |
| MoneyControl | $3.27 Billion USD |
| MarketWatch | $3.27 Billion USD |
| marketcap.company | $3.27 Billion USD |
| Reuters | $3.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Scien… Read more